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Abstract: PURPOSE The aim of this study was to derive reference values of 18F-fluoro-ethyl-L-tyrosine
positron emission tomography (18F-FET-PET) uptake in normal brain and head structures to allow
for differentiation from tumor tissue. MATERIALS AND METHODS We examined the datasets of
70 patients (median age 53 years, range 15-79), whose dynamic 18F-FET-PET was acquired between
January 2016 and October 2017. Maximum standardized uptake value (SUVmax), target-to-background
standardized uptake value ratio (TBR), and time activity curve (TAC) of the 18F-FET-PET were as-
sessed in tumor tissue and in eight normal anatomic structures and compared using the t-test and
Mann-Whitney U-test. Correlation analyses were performed using Pearson or Spearman coefficients, and
comparisons between several variables with Pearson’s chi-squared tests and Kruskal-Wallis tests as well
as the Benjamini-Hochberg correction. RESULTS All analyzed structures showed an 18F-FET uptake
higher than background (threshold: TBR > 1.5). The venous sinuses and cranial muscles exhibited a
TBR of 2.03±0.46 (confidence interval (CI) 1.92-2.14), higher than the uptake of caudate nucleus, pineal
gland, putamen, and thalamus (TBR 1.42±0.17, CI 1.38-1.47). SUVmax, TBR, and TAC showed no dif-
ference in the analyzed structures between subjects with high-grade gliomas and subjects with low-grade
gliomas, except the SUVmax of the pineal gland (t-tests of the pineal gland: SUVmax: p = 0.022; TBR:
p = 0.411). No significant differences were found for gender and age. CONCLUSION Normal brain tissue
demonstrates increased 18F-FET uptake compared to background tissue. Two distinct clusters have been
identified, comprising venous structures and gray matter with a reference uptake of up to SUVmax of
2.99 and 2.33, respectively.
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The aim of this study was to derive reference values of 18F-fluoro-ethyl-L-tyrosine positron
emission tomography (18F-FET-PET) uptake in normal brain and head structures to allow
for differentiation from tumor tissue.
Materials andmethods
We examined the datasets of 70 patients (median age 53 years, range 15–79), whose
dynamic 18F-FET-PET was acquired between January 2016 and October 2017. Maximum
standardized uptake value (SUVmax), target-to-background standardized uptake value
ratio (TBR), and time activity curve (TAC) of the 18F-FET-PET were assessed in tumor tis-
sue and in eight normal anatomic structures and compared using the t-test and Mann-Whit-
ney U-test. Correlation analyses were performed using Pearson or Spearman coefficients,
and comparisons between several variables with Pearson’s chi-squared tests and Kruskal-
Wallis tests as well as the Benjamini-Hochberg correction.
Results
All analyzed structures showed an 18F-FET uptake higher than background (threshold:
TBR > 1.5). The venous sinuses and cranial muscles exhibited a TBR of 2.03±0.46 (confi-
dence interval (CI) 1.92–2.14), higher than the uptake of caudate nucleus, pineal gland,
putamen, and thalamus (TBR 1.42±0.17, CI 1.38–1.47). SUVmax, TBR, and TAC showed
no difference in the analyzed structures between subjects with high-grade gliomas and sub-
jects with low-grade gliomas, except the SUVmax of the pineal gland (t-tests of the pineal
gland: SUVmax: p = 0.022; TBR: p = 0.411). No significant differences were found for gen-
der and age.
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Conclusion
Normal brain tissue demonstrates increased 18F-FET uptake compared to background tis-
sue. Two distinct clusters have been identified, comprising venous structures and gray mat-
ter with a reference uptake of up to SUVmax of 2.99 and 2.33, respectively.
Introduction
Positron emission tomography (PET) using the radiotracer 18F-fluoro-ethyl-L-tyrosine
(18F-FET), an amino acid analogue, is becoming increasingly relevant in the initial assessment
of primary brain tumors, and for differentiating tumor recurrences from post-therapeutic
changes [1, 2]. In addition, 18F-FET-PET provides valuable input for treatment planning and
therapy response assessment in patients, e.g. targeted tumor biopsy, surgery, and radiation
therapy planning [3–5]. Several studies have documented the clinical feasibility and impact of
18F-FET, but its use is still limited to specialized centers [6–8].
Proton MR spectroscopy (MRS) has also been shown to be of value for grading and therapy
response assessment of supratentorial gliomas [8–10]. Nevertheless, methodical challenges
such as high susceptibility to artifacts in tumors close to air-filled spaces, variable acquisition
techniques, volume averaging caused by voxel size and deviations in the calculation of metabo-
lite ratios have limited widespread clinical implementation of MRS [8, 11].
Anatomical magnetic resonance imaging (MRI) currently serves as the imaging standard of
reference for the non-invasive assessment and follow-up of brain tumors [12, 13]. However,
combined 18F-FET-PET and MRI allows a more accurate delineation of tumor margins, along
with a simultaneous identification of the region with the highest amino acid uptake, and hence
a more accurate grading of brain tumors than MRI alone [14–17]. 18F-FET-PET was shown to
aid the differentiation of low-grade gliomas (LGG) and high-grade gliomas (HGG). Several
cut-off values of the target-to-background (TBR) ratio were established for this purpose [18,
19]. 18F-FET-PET uptake of inflammatory lesions appeared negligible in several studies,
which is particularly useful when MRI results are equivocal [20–22].
However, normal anatomic brain structures such as deep grey matter, glandular structures,
and venous vessels may exhibit 18F-FET uptake higher than normal parietal lobe, which serves
as background reference tissue [6, 7, 15]. Currently, systematic data on 18F-FET characteristics
of such normal cerebral structures and their relation to brain tumors is lacking in the litera-
ture. On the other hand, knowledge about normal morphological structures becomes even
more important with the event of PET/MRI, which renders 18F-FET-PET imaging “more ana-
tomical”. Without such knowledge, physiological uptake may be confounded with tumor-asso-
ciated uptake. This can be the case in several brain tumors, particularly in those affecting the
midline, such as corpora quadrigemina or basal ganglia tumors (i.e., papillary tumors of the
pineal region, lymphomas, glioblastomas or oligodendrogliomas).
In our study, we aimed to derive reference values of 18F-FET uptake of normal brain and
head structures in subjects in order to facilitate differentiation from tumor tissue.
Materials andmethods
All procedures performed were in accordance with the ethical standards of the institutional
research committee and with the 1964 Helsinki declaration and its later amendments.
Informed consent was obtained from all patients included in the study. This study was
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approved by the relevant ethical authorities (Kantonale Ethikkommission Zurich). Written
consent was obtained with the approval number 2017–00152. Since September 2014, all
patients are asked upon admission to give signed informed consent to allow the use of their
health-related data for research. Patients who refused consent were not included in our study.
Inclusion and exclusion criteria
For this retrospective study on subjects with brain tumors, data were collected from the picture
archiving and communication system (PACS) and the clinical information system of our insti-
tution. All patients had received an 18F-FET-PET scan and an MRI scan between January
2016 and October 2017. The MRI exam was required to contain a minimum pulse sequence
set T1-weighted (T1w) with and without contrast, T2-weighted (T2w), fluid-attenuated in-
version recovery (FLAIR)-weighted image datasets. Exclusion criteria were incomplete
18F-FET-PET exam (e.g., incomplete dynamic acquisition or incomplete coverage of the
brain), and any intervention between 18F-FET-PET and MRI scan.
Image acquisition
All 18F-FET-PET were acquired using a Discovery VCT scanner (GE Healthcare, Waukesha,
WI) or a Discovery 690 Standard scanner (GE Healthcare). According to the standardized pro-
tocol at our institution, all subjects were injected intravenously with 130 MBq of 18F-FET
(mean 133 MBq, range 121–143 MBq) after a minimum of four hours of fasting to ensure stan-
dardized metabolic conditions. 18F-FET-PET data was acquired 20–40 minutes (min) after
injection, using four 5 min frames. Emission data were corrected for randoms, dead time, scat-
ter, and attenuation. Iterative reconstructions of the attenuation-corrected axial 18F-FET-PET
datasets were done using a 128 × 128 pixels matrix (voxel spacing: 2.3438 � 2.3438 � 3.27).
Eight anatomic brain and head structures were analyzed, and the following 18F-FET-PET
parameters were measured: standardized uptake value (SUV), target to background ratio
(TBR), and time activity curve (TAC) pattern. SUVmax was defined as the average of the five
hottest voxels of a particular structure. Five voxels were chosen since studies showed that aver-
aging SUV from several voxel results in significantly lower variability between different mea-
surements and therefore improves the accuracy and repeatability of SUV [23, 24].
TBR is the quotient of the SUVmax of a structure and the SUVmean of normal contralateral
parietal lobe [25]. The mean 18F-FET uptake was measured using a crescent-shaped back-
ground VOI in the parietal lobe, including grey and white matter, as suggested by the joint
EANM/EANO/RANO practice guidelines/SNMMI procedure standards [26].
Furthermore, the dynamic parameter TACs of 18F-FET uptake in the regions of interest
were generated using a spherical VOI. For each VOI, the SUVmax of all four frames was mea-
sured. These values define three different slope patterns of the TAC: 1) wash-in, 2) plateau,
and 3) wash-out. A plateau pattern was defined as a maximum change of +/-10%. A wash-in
pattern refers to an increase by more than 10% during the aforementioned four 5 min frames,
while a wash-out pattern refers to a decrease by more than 10% [19]. Symmetric brain struc-
tures were measured on the side with the higher 18F-FET uptake, to address potential confu-
sion with tumor tissue. An exception was when tumor abutted this location. In this case, the
contralateral structure was measured.
Data from ten patients was independently re-analyzed by a second reader, who used the
same criteria, to test the inter-reader reliability of SUV, TBR, and TACmeasurements. In addi-
tion, the first reader re-analyzed twenty datasets after a time interval of six weeks to assess
intra-reader concordance. For all re-analyses, patients were selected using a random generator
(https://www.ultimatesolver.com) in order to avoid selection bias.
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Correlation with MRI was used to identify the aforementioned brain and head structures
and to anatomically define the location of the brain tumor. MRI exams were conducted using
different 3 Tesla MRI scanners at our institution.
Image analysis
The MRI scan closest to the included 18F-FET-PET scan were analyzed for this study. Eight
normal brain and head structures (caudate nucleus, cavernous sinus, pineal gland, putamen,
sigmoid sinuses, superior sagittal sinus, temporal muscles, and thalamus) were investigated in
each patient. Clinical pilot tests have shown that these structures have a high physiological
18F-FET uptake; examples are provided in Fig 1. In our study cohort, four tumors were located
in the pineal gland region and three close to the superior sagittal sinus, hence no values were
recorded from these structures in these subjects.
Analysis of 18F-FET-PET and MRI data were done using PMOD1 software (Version 3.8,
PMOD technologies LLC, Zurich, Switzerland), which allows for separate, combined, and
fused review of image datasets and a voxel-wise analysis.
Statistical analysis
Descriptive analyses of patient characteristics and 18F-FET characteristics of tumors and ana-
tomical structures were based on mean (with standard deviation), median (with range), and
mode score (with percentage), depending on the particular scale of measurement. The distri-
butions were inspected visually using histograms and boxplots; and if acceptable, the t-test was
used for statistical comparison of ratio variables such as SUVmax and TBR. When the normal
distribution was equivocal, the non-parametric U-test of Mann andWhitney was applied. A
two-tailed p-value of less than 0.05 was defined as statistically significant. A possible connec-
tion between tumoral SUVmax and SUVmax of the eight analyzed structures was examined in
two ways: First, the average tumoral SUVmax (2.9) was used as threshold in order to define two
groups for the comparison of tumor and normal structures. In addition, six groups were
binned by increasing tumoral SUVmax.
Reference values were determined by a 95% reference interval using the mean (M) and two
standard deviations (SD) of the 18F-FET uptake values (precisely, M ±1.96 SD). This calcula-
tion yields the 2.5th and 97.5th percentiles of the distribution, which serves as reference [27].
Fig 1. Example of measurement of 18F-FET uptake in anatomic brain structures. A T1-weighted (T1w) MR image,
B T2-weighted (T2w) MR image, C fused image PET/MR image. Examples of two volumes-of-interest (VOI) for
18F-FET uptake calculation in physiological structures: putamen (black arrow) and thalamus (white arrow).
https://doi.org/10.1371/journal.pone.0230618.g001
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Statistical analyses were undertaken using the ‘Statistical Package for the Social Sciences’
(SPSS1, version 25, IBM, Armonk, NY). Differences among several variables were tested via
crosstabulation with Pearson’s chi-squared test (χ2). The Kruskal-Wallis test served as a non-
parametric alternative test for the one-way analysis of variance (ANOVA). Statistical multiplic-
ity, which is based on a set of simultaneous statistical inferences due to multiple comparisons
(also known as the problem of multiple comparisons), was minimized with the Benjamini-
Hochberg correction method [28].
Results
Seventy brain tumor patients were included who were between 15 and 79 years-old (M±SD
49.8±16.2) and 42 were male (60.0%). 24 of 70 (34.3%) brain tumors were initial diagnoses, 46
(65.7%) were from follow-up examinations, e.g. suspected recurrence, of previously known
and, partly, pretreated tumors. Primary brain tumors (65 of 70 patients, 92.8%) were classified
according to the World Health Organization (WHO) 2016 system: 41 HGG (58.6%) and 24
LGG (34.3%) were verified histologically [29]. 12 of 70 patients (17.1%) patients had glioma
suspected by MRI, but without histopathological confirmation before the 18F-FET PET scan.
Subsequent clinical and radiologic follow-up with MRI and histopathology revealed LGG in all
cases. Five of 70 patients (7.2%) had brain metastases. Demographic details, rationale for
18F-FET-PET scan, and tumor characteristics are given in Table 1.
The median time interval between the 18F-FET-PET scan and the MRI scan was 29.5 days.
Our analyses demonstrated low inter- and intra-reader reliability (with deviation of less than
10%).
The 18F-FET uptake (measured as SUVmax) and the TBR of the eight examined structures
and of the tumors are given in Table 2. SUVmax ranged from 0.72 in the caudate nucleus and
3.81 in the superior sagittal sinus, with a mean of 1.93 across all eight structures. The mean
SUVmax of tumor tissue was 2.95 +/- 1.77 (median 2.67, range 0.85 to 9.40). Four tumors
showed no 18F-FET uptake but were histologically classified as WHO grade II (n = 1), WHO
grade III (n = 2) gliomas and metastasis (n = 1). The mean SUVmax of metastases (n = 5) was
2.57 ±1.7 (median 2.67, range 2.3 to 4.6). The mean TBR was 2.08 ±1.3 (median 2.14, range 0.6
to 3.3).
Reference values for the eight brain and head structures, derived as described above, ranged
from 1.15 to 2.03 (caudate nucleus) and 1.99 to 2.81 (superior sagittal sinus). All values are
given in Table 3.
HGG had a mean of SUVmax in the tumor tissue of 3.53 ±1.8 (median 3.77, range 1.5 to
9.4), with a maximum of 9.4 found in a case of glioblastoma in a 61-year-old man. The mean
TBR of HGG tumor tissue was 2.98 ±1.1 (median 2.99, range 1.2 to 5.9), while TBR of two
lesions was below 1.5. LGG exhibited a mean SUVmax of 1.97±1.5 (median 2.25, range 0.85 to
4.6) with a maximum of 4.6 in a low grade glioma from a 51-year-old woman. The mean TBR
of tumor tissue in LGG was 2.23 ±0.9 (median 2.03, range 0.92 to 4.0). Notably, SUVmax and
TBR of the tumor tissue differed significantly between HGG and LGG (independent samples
t-test (SUVmax: t(60) = -3.613, p = .001; TBR: t(54) = -2.512, p = .01). SUVmax of the pineal
gland was significantly lower in LGG subjects than in HGG subjects (independent samples t-
test, t(59) = -2.357, p = 0.022). However, no significant differences were found between HGG
and LGG subjects in the seven remaining brain structures. Details are given in Table 4.
In addition, it was found that the higher the tumoral SUVmax, the higher the SUVmax of the
eight normal structures in our study. Mean SUVmax and TBR values showed no significant dif-
ferences according to age (univariate analysis over 7 age decades (Table 1) as well as non-
parametric rank Kruskal-Wallis test) or gender (independent samples t-test).
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Comparison of SUVmax (Fig 2) and the TBR (Fig 3) of the eight investigated structures
revealed two clusters, each consisting of four structures: The first cluster comprised the three
venous sinuses and the temporal muscles (hereafter referred to as the “venous cluster”) had a
group mean of 2.25 (95% confidence interval [CI], 2.16–2.33; SD = 0.37). The second cluster
consisted of the pineal gland, putamen, caudate nucleus, and thalamus (hereafter referred to as
the “deep gray matter cluster”) had a group mean of 1.61 (95% CI, 1.52–1.70; SD = 0.36). The
differences in SUVmax of the two clusters were significant following a paired sample t-test (t
(69) = 15.869, p< .001).
The venous cluster showed a group TBR mean of 2.03 (95% CI, 1.92–2.14; SD = 0.46) and
deep gray matter cluster, a group mean of 1.42 (95% CI, 1.38–1.47; SD = 0.17). Differences in
the TBR values for the venous cluster and deep gray matter cluster were significant (paired
Table 1. Patient demographics, tumors, and reason for 18F-FET-PET.
Total patients (n) 70
Males (n (%)) 42 (60%)
Females (n (%)) 28 (40%)
Age [years] (mean (range)) 49.8 (15–79)
10–19 years (n (%)) 3 (4.3%)
20–29 years (n (%)) 6 (8.6%)
30–39 years (n (%)) 11 (15.7%)
40–49 years (n (%)) 12 (17.1%)
50–59 years (n (%)) 15 (21.4%)
60–69 years (n (%)) 16 (22.9%)
70–79 years (n (%)) 7 (10.0%)
Histological diagnosis (n (%))
Gliomas according to WHO grading 65 (92.8%)
• WHO grade I 9 (12.9%)
• low grade glioma (n = 9)
• WHO grade II 15 (21.4%)
• low grade astrocytoma (n = 7)
• oligodendroglioma (n = 4)
• oligoastrocytoma (n = 2)
• pleomorphic xanthoastrocytoma (n = 1)
• ependymoma (n = 1)
• WHO grade III 19 (27.1%)
• anaplastic astrocytoma (n = 12)
• anaplastic oligodendroglioma (n = 5)
• anaplastic oligoastrocytoma (n = 2)
• WHO grade IV 22 (31.4%)
• primary glioblastoma (n = 20)
• secondary glioblastoma (n = 2)
Metastases 5 (7.2%)
Indication for 18F-FET-PET scan (n (%))
Initial diagnosis/grading of the tumor 16 (22.9%)
Therapy planning/assessment of therapy response 18 (25.7%)
Recurrence assessment 36 (51.4%)
18F-FET, 18F-fluoro-ethyl-L-tyrosine; WHO, World Health Organization
(here: WHO classification of tumors of the central nervous system (27)).
https://doi.org/10.1371/journal.pone.0230618.t001
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sample t-test: t(69) = 12.221, p< .001). The CIs for both—SUVmax and TBR mean of the clus-
ters—were mutually exclusive and narrow with less than 5% deviation from the mean of
venous cluster and slightly above a 5% from the mean of deep gray matter cluster. Intra-cluster
correlations (Pearson r or Spearman Rho with a non-parametric distribution in the scatter
plot) were all highly significant with p< .01. Details are given in Fig 4.
All eight structures exhibited three predefined TAC patterns (wash-in, plateau, and wash-
out), however, with differing distribution of the patterns: The share of wash-in varied from 3%
(superior sagittal sinus) to 47.1% (caudate nucleus), the plateau from 41.4% (sigmoid sinuses)
to 74.3% (temporal muscles), whereas the proportion of wash-out reached from 2.9% (caudate
nucleus) to 49.3% (superior sagittal sinus). There was no significant difference in the distribu-
tion of TAC between patients with HGG versus LGG (Mann-Whitney U-test, details in
Table 3). In addition, the distribution of the TAC patterns reflected the two clusters. Crossta-
bulation Pearson’s chi-squared test showed that the clusters differ significantly regarding TAC
(χ2(2) = 126.74, p< .001). Details are given in Fig 5.
Table 2. 18F-FET-PET parameters in tumor tissue and normal brain and head structures.
18F-FET-PET SUVmax TBR TAC (n (%))
parameter Mean Min Max Mean Min Max Mean 1 wash-in 2 plateau 3 wash-out
Superior sagittal sinus 2.40 1.30 3.81 2.20 1.52 4.89 2.46 2 (2.9%) 32 (45.7%) 33 (47.1%)
Sigmoid sinuses 2.27 1.38 3.51 2.05 1.33 4.36 2.39 7 (10.0%) 29 (41.4%) 34 (48.6%)
Cavernous sinus 2.13 0.95 3.49 1.92 0.95 3.80 2.39 3 (4.3%) 37 (52.9%) 30 (42.9%)
Temporal muscles 2.18 1.32 3.52 1.97 1.03 3.45 2.11 5 (7.1%) 52 (74.3%) 13 (18.6%)
Pineal gland 1.64 0.93 3.24 1.47 0.73 2.31 1.85 21 (30.0%) 34 (48.6%) 11 (15.7%)
Putamen 1.61 0.74 3.01 1.41 1.07 1.85 1.67 28 (40.0%) 37 (52.9%) 5 (7.1%)
Caudate nucleus 1.59 0.72 3.39 1.40 0.97 1.86 1.56 33 (47.1%) 35 (50.0%) 2 (2.9%)
Thalamus 1.61 0.94 2.60 1.43 1.03 2.18 1.67 26 (37.1%) 41 (58.6%) 3 (4.3%)
N = 70; tumor tissue: n = 58, superior sagittal sinus: n = 67, pineal gland: n = 66 (If tumors were abutting the pineal gland or the superior sagittal sinus, no values were
recorded from these structures.)
18F-FET, 18F-fluoro-ethyl-L-tyrosine; Max, maximum; Min, minimum; SUVmax, maximum standardized uptake value; TAC, time activity curve; TBR tumor-to-brain
or target-to-background standardized uptake value ratio.
https://doi.org/10.1371/journal.pone.0230618.t002
Table 3. 18F-FET-PET reference values for normal brain and head structures.
18F-FET-PET SUVmax reference values (M±2 SD)
parameter Mean SD lower limit upper limit
Superior sagittal sinus 2.40 0.41 1.99 2.81
Sigmoid sinuses 2.27 0.48 1.79 2.75
Cavernous sinus 2.13 0.49 1.64 2.62
Temporal muscles 2.18 0.42 1.76 2.60
Pineal gland 1.64 0.47 1.17 2.11
Putamen 1.61 0.43 1.18 2.04
Caudate nucleus 1.59 0.44 1.15 2.03
Thalamus 1.61 0.36 1.25 1.97
N = 70; tumor tissue: n = 58, superior sagittal sinus: n = 67, pineal gland: n = 66 (If tumors were abutting the pineal
gland or the superior sagittal sinus, no values were recorded from these structures.)
18F-FET, 18F-fluoro-ethyl-L-tyrosine; M, mean; SD, standard deviation; SUVmax, maximum standardized uptake
value.
https://doi.org/10.1371/journal.pone.0230618.t003
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Discussion
18F-radiolabeled amino acid FET has become a valuable and clinically established tracer for
PET imaging in patients with brain tumors [2, 31, 32]. Sensitivity of 18F-FET-PET for neoplas-
tic brain tissue is high, while specificity is low, because 18F-FET also accumulates in non-
tumoral tissue [33–37]. In our study, we systematically characterized 18F-FET-PET features in
eight anatomic brain and head structures (caudate nucleus, cavernous sinus, pineal gland,
putamen, sigmoid sinuses, superior sagittal sinus, temporal muscles, and thalamus) that
showed prominent accumulation in clinical pilot tests in tumor patients, owing to their com-
parably high physiological 18F-FET uptake.
Literature on 18F-FET-PET uptake of non-neoplastic lesions is limited and mainly
describes incidental findings such as aneurysms and abscesses, while some retrospective data
exists on demyelinating lesions [21, 38–40]. Little is known about 18F-FET imaging character-
istics of normal brain structures. Some studies have investigated normal brain tissue, reporting
Table 4. 18F-FET-PET parameters in high-grade and low-grade gliomas.
18F-FET-PET parameter HGG (n = 41) LGG (n = 24) p-value
Tumor tissue SUVmax (mean ± SD) 3.53±1.8 1.97±1.5 0.001
��
TBRmax (mean ± SD) 2.98±1.1 2.23±0.9 0.015
�
TAC (mean rank) 11.00 9.20 0.441
Superior sagittal sinus SUVmax (mean ± SD) 2.42±0.4 2.41±0.41 0.881
TBRmax (mean ± SD) 2.12±0.4 2.39±0.7 0.077
TAC (mean rank) 32.36 30.15 0.589
Sigmoid sinuses SUVmax (mean ± SD) 2.32±0.5 2.24±0.5 0.548
TBRmax (mean ± SD) 1.99±0.4 2.21±0.7 0.104
TAC (mean rank) 34.50 30.44 0.356
Cavernous sinus SUVmax (mean ± SD) 2.13±0.6 2.12±0.5 0.948
TBRmax (mean ± SD) 1.83±0.5 2.09±0.6 0.056
TAC (mean rank) 31.98 34.75 0.518
Temporal muscles SUVmax (mean ± SD) 2.25±0.4 2.13±0.4 0.255
TBRmax (mean ± SD) 1.93±4.2 2.09±0.5 0.210
TAC (mean rank) 32.12 34.50 0.532
Pineal gland SUVmax (mean ± SD) 1.77±0.5 1.48±0.3 0.022
�
TBRmax (mean ± SD) 1.52±0.4 1.43±0.4 0.411
TAC (mean rank) 31.08 30.86 0.961
Putamen SUVmax (mean ± SD) 1.66±0.4 1.53±0.5 0.292
TBRmax (mean ± SD) 1.40±0.2 1.52±0.2 0.690
TAC (mean rank) 33.48 32.19 0.766
Caudate nucleus SUVmax (mean ± SD) 1.63±0.4 1.53±0.5 0.409
TBRmax (mean ± SD) 1.38±0.3 1.42±0.3 0.459
TAC (mean rank) 32.55 33.77 0.775
Thalamus SUVmax (mean ± SD) 1.63±0.3 1.55±0.4 0.383
TBRmax (mean ± SD) 1.39±0.2 1.47±0.2 0.158
TAC (mean rank) 35.90 28.04 0.63
N = 70; tumor tissue: n = 58, superior sagittal sinus: n = 67, pineal gland: n = 66 (If tumors were abutting the superior sagittal sinus or the pineal gland, no values were
recorded from these structures.). SUVmax and TBR: independent samples t-test, TAC: Mann-Whitney U-test
Sig. (two-tailed): �p < .05, ��p < .01.
18F-FET, 18F-fluoro-ethyl-L-tyrosine; HGG, high-grade glioma; LGG, low-grade glioma; SD, standard deviation; SUVmax, maximum standardized uptake value;
TBRmax, maximum tumor-to-brain or target-to-background standardized uptake value ratio.
https://doi.org/10.1371/journal.pone.0230618.t004
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rather homogenous results within white matter and superficial gray matter. Separate brain
regions or distinct structures were not analyzed [41, 42].
We found that all eight normal structures exhibited SUVmax and TBR values considerably
above background. For TBR in our study, a threshold value of 1.5 was considered indicative of
increased 18F-FET uptake. This threshold is based on several former studies, in particular, a
biopsy-controlled study from Pauleit et al. (2005), where a TBR above 1.5 discriminated neo-
plastic from normal brain tissue [38, 42, 43]. Our study population exhibited values both over
and under the TBR threshold values of 1.5 in seven structures and only the superior sagittal
sinus exhibited a TBR consistently above this threshold.
On average, 18F-FET uptake in anatomic structures was lower than in tumor tissue. How-
ever, the range of 18F-FET uptake from tumor and non-tumor overlapped to a great extent,
precluding reliable discrimination based on TBR alone [44]. These findings indicate that
18F-FET-PET sensitivity for tumor tissue is high, but not strongly specific. In addition, blood
brain barrier breakdown may not be required for exhibiting ‘pathological’ 18F-FET uptake [7,
33, 45, 46]. Admittedly, the highest TBR in our study was found in the superior sagittal sinus,
which is outside the blood brain barrier. Future reference validation might take into account
such vascular brain structures that provide information on the blood pool, in addition to the
established parietal lobe brain tissue.
Fig 2. Scatterplots of SUVmax. A Scatterplot of SUVmax of venous cluster with SUVmax of deep gray matter cluster. B
Significant difference in the SUVmax were found for venous cluster (M = 2.25, SD = 0.37) and deep gray matter cluster
(M = 1.61, SD = 0.36), paired sample t-test, 1p = 1.0129E-24.
https://doi.org/10.1371/journal.pone.0230618.g002
Fig 3. Scatterplots of TBR. A Scatterplot of TBR of venous cluster with TBR of deep gray matter cluster. B Significant
difference in the TBR values were identified for venous cluster (M = 2.03, SD = 0.46) and deep gray matter cluster
(M = 1.42, SD = 0.17), paired sample t-test, 1 p = 6.312E-19.
https://doi.org/10.1371/journal.pone.0230618.g003
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Fig 4. Intra-cluster correlations. A Intra-cluster correlations of the venous cluster vary between 0.42 and 0.67, all highly significant. B Intra-
cluster correlations of the deep gray matter cluster vary between 0.38 and 0.82, all highly significant. Sig. (two-tailed): ��p< .01. Spearman Rho
rank correlation applicable for non-parametric distribution in the scatter plot. Strength of correlation< 0.3 = no correlation, 0.3–0.5 weak, 0.5–0.8
moderate,> 0.8 strong correlation [30].
https://doi.org/10.1371/journal.pone.0230618.g004
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In addition, our study provides some evidence that 18F-FET uptake in normal structures is
actually linked to tumoral 18F-FET uptake. The higher the tumoral SUVmax, the higher was
the SUVmax of the eight normal structures. Results of both analyses on this issue were consis-
tent, with the course of SUVmax in the subgroups comparable to our entire sample, thus con-
firming the robustness of our data. However, the increase from group to group is small and is
based on a limited number of patients per group. In addition, the size of the groups is
unequally distributed, especially the lowest and highest groups are small, so that the outliers
affect the mean. Therefore, this result warrants further substantiation by studies with a larger
number of patients, including stratification according to different types of primary and sec-
ondary tumors. Additional research might illuminate if there is a possible interrelation influ-
enced by tumoral SUVmax, either related to overall higher SUVmax in a particular patient’s
brain or another factor. Nevertheless, the finding that the uptake of certain normal structures
was high, with higher uptake in brain tumors substantiates the assumption that blood pool
may play an important role in the degree of tumoral uptake. Tumoral 18F-FET uptake may be
consistently overestimated if only combined parietal lobe grey and white matter is considered
as the reference [26]. Future studies are encouraged to investigate the use of other referential
tissues such as basal ganglia.
We have found no significant difference of 18F-FET-PET parameters between HGG and
LGG cases except for the pineal gland and the intrinsic tumors values. These findings are in
line with the large overlap of HGG and LGG regarding SUVmax and TBR in different studies
[42, 44]. No significant differences were found for gender and age. Patients are not equally dis-
tributed among age groups, e.g., a few patients were in age range of 10–30 years and above 70
years. Therefore, conclusions about age groups need to be drawn with caution.
Another major result of our study is that the eight analyzed structures constitute two clus-
ters by SUVmax, TBR, and TAC. The composition of the two clusters is similar in all of the
above parameters: The first cluster (i.e., venous cluster) contains the three sinuses and tempo-
ral muscles, which are extraaxial structures not subject to the blood brain barrier. The second
Fig 5. Time activity curves. A The three different patterns of the TAC of 18F-FET uptake (1 wash-in, 2 plateau, and 3
wash-out) were unequally distributed among the eight structures. BDistribution of the TAC pattern reflects the two
clusters venous cluster and deep gray matter cluster. The crosstabulation Pearson’s chi-squared test suggests that the
two clusters are not related regarding TAC (χ2 (2) = 126.74, p< .001). N = 70; superior sagittal sinus: n = 67, pineal
gland: n = 66 (If tumors were in the superior sagittal sinus or in the pineal gland, no values were recorded from these
structures).
https://doi.org/10.1371/journal.pone.0230618.g005
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cluster (i.e., deep gray matter cluster) is composed of the caudate nucleus, pineal gland, puta-
men, and thalamus, which are intraaxial structures isolated by the blood brain barrier, except
for the pineal gland. There was a marked difference between the mean and range of the two
clusters. The CI of the means were mutually exclusive and with narrow ranges, both being
indicators for a relevant statistical approximation. The two clusters suggest reference values for
SUVmax (venous cluster: 2.25±0.08, deep gray matter cluster: 1.61±0.09) and for TBR (2.03
±0.11 and 1.42±0.05, respectively) (Figs 2 and 3).
The composition of the clusters indicates that the difference in 18F-FET uptake is influ-
enced by blood flow. The sinuses and the muscles show a comparably high 18F-FET uptake, in
line with the common finding of positive correlation between cerebral blood volume and
amino 18F-FET uptake with 11C-methyl-L-methionine (11C-MET) [47]. The amino acid
18F-FET is not metabolized or incorporated into proteins, but its accumulation in tissue is due
to the transport mediated by the L-type amino acid transport system [6, 48, 49]. Moreover, the
distribution of TAC patterns among the two clusters, with a higher portion of wash-out in the
cluster of the sinuses and muscles, is in line with findings in the literature, although only a part
of the variance of 18F-FET wash-out may be explained by perfusion [50, 51].
The low specificity of 18F-FET-PET can present challenges such as inability to discriminate
between tumoral and normal tissue in specific brain structures. 18F-FET uptake values of the
eight brain and head structures acquired by the M ± 2 SD approach may serve as reference val-
ues in a clinical setting. Two clearly distinct clusters were identified and comprise venous
structure and gray matter. The reference uptake of the two clusters reaches 2.99 and 2.33,
respectively.
In clinical practice, it is recommended that uptake values and imaging characteristics
reported for gliomas should take into account the background activity of individual adjacent
tissue for standardization [52]. Further studies may repeat our analysis with PET/MRI, which
is increasingly available. PET/MRI allows for multiparametric imaging at the same time by
combining conventional MRI, advanced MRI, and PET imaging, all images acquired under
the same physiological conditions and the same iso-center for optimal realignment. However,
the issue of attenuation correction is not fully solved [53–55].
Limitations
We acknowledge that our study involved only patients with brain tumors; there was no normal
control group. It might have been beneficial to study healthy subjects in order to avoid poten-
tial confounding factors. However, we refrained from this option because of ethical consider-
ations. Additionally, relevant structures in our analysis were thoroughly verified on MRI to
confirm the absence of tumor tissue there and in their vicinity. Another limitation of our
study is that most patients had undergone surgery and/or biopsy (some repeatedly), together
with different types of radiotherapy and chemotherapy, which may have altered 18F-FET
uptake.
Conclusion
This study aimed to examine the uptake characteristics of 18F-FET measured by SUVmax,
TBR, and TAC within normal structures of the brain and head in tumor patients. We found
that the investigated eight structures exhibit a systematic 18F-FET uptake within the range of
tumor tissue and form two distinct clusters: the cluster with well-perfused structures sinuses
and muscles show higher 18F-FET uptake than the cluster comprising intraaxial structures.
Reference values for 18F-FET uptake of the two clusters reach SUVmax of 2.99 and 2.33,
respectively.
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To our knowledge, this is the first study to systematically evaluate normal brain and head
structures. Our findings confirm that the specificity of 18F-FET-PET is limited by the inability
to differentiate tumor tissue from normal structures, based only on their uptake characteristics
[7, 33]. Future work is indicated to examine the additional use of blood pool for reference pur-
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25. Pöpperl G, Götz C, RachingerW, Gildehaus F-J, Tonn J-C, Tatsch K. Value of O-(2-[18F]fluoroethyl)-l-
tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004; 31(11):1464–70.
https://doi.org/10.1007/s00259-004-1590-1 PMID: 15248032
26. Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice
guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino
acids and [18F]FDG: version 1.0. Eur J Nucl MedMol Imaging. 2018:1–18. https://doi.org/10.1007/
s00259-018-4207-9 PMID: 30519867
27. Horn PS, Pesce AJ. Reference intervals: an update. Clin Chim Acta. 2003; 334(1):5–23. https://doi.org/
10.1016/S0009-8981(03)00133-5
28. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to
Multiple Testing. J Royal Stat Soc. 1995; 57(1):289–300. https://doi.org/10.1111/j.2517-6161.1995.
tb02031.x
29. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, CaveneeWK, et al. The 2016
World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta
Neuropathol. 2016; 131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1 PMID: 27157931.
30. Cohen J. Set Correlation and Contingency Tables. Appl Psychol Meas. 1988; 12(4):425–34. https://doi.
org/10.1177/014662168801200410
31. Albatly AA, Alsamarah AT, Alhawas A, Veit-Haibach P, Buck A, Stolzmann P, et al. Value of 18F-FET
PET in adult brainstem glioma. Clin Imaging. 2018; 51:68–75. https://doi.org/10.1016/j.clinimag.2018.
01.015 PMID: 29448122
32. Muoio B, Giovanella L, Treglia G. Recent Developments of 18F-FET PET in Neuro-oncology. Curr Med
Chem. 2018; 25:1–13. https://doi.org/10.2174/0929867325666171123202644 PMID: 29173147
33. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET)
PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl
Med. 2012; 53(2):207–14. https://doi.org/10.2967/jnumed.111.096859 PMID: 22302961.
34. Unterrainer M, Diekmann C, Dorostkar M, Vettermann FJ, Kumpfel T, Tonn J-C, et al. Neurosarcoidosis
Mimics High-Grade Glioma in Dynamic 18F-FET PET Due to LAT Expression. Clin Nucl Med. 2018; 43
(11):840–1. https://doi.org/10.1097/RLU.0000000000002266 PMID: 30179915
35. Burghaus L, Kabbasch C, Deckert M, RugeMI, Fink GR, Langen K-J, et al. FET PET in Primary Central
Nervous System Vasculitis. Clin Nucl Med. 2018; 43(9):e322–e3. https://doi.org/10.1097/RLU.
0000000000002197 PMID: 30080188
36. Hutterer M, Bumes E, Riemenschneider MJ, Grosse J, Hellwig D, Galldiks N, et al. AIDS-Related Cen-
tral Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-L-Tyrosine Amino Acid PET
Uptake Due to LAT1/2 Expression of Inflammatory Cells. Clin Nucl Med. 2017; 42(12):e506–e8. https://
doi.org/10.1097/RLU.0000000000001873 PMID: 29076908.
37. ChanM, Hsiao E. Neurosarcoidosis on FET and FDG PET/CT. Clin Nucl Med. 2017; 42(3):197–9.
https://doi.org/10.1097/RLU.0000000000001516 PMID: 28045730.
38. Weckesser M, Langen K-J, Rickert CH, Kloska S, Straeter R, Hamacher K, et al. O-(2-[18F]fluorethyl)-
L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl MedMol Imaging. 2005;
32(4):422–9. https://doi.org/10.1007/s00259-004-1705-8 PMID: 15650870.
39. Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, StummerW, et al. 18F-FET PET differentia-
tion of ring-enhancing brain lesions. J Nucl Med. 2006; 47(5):776–82. PMID: 16644747.
40. Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger H-J, et al. Prognostic Value of 18F-
Fluoroethyl-l-Tyrosine PET and MRI in Small Nonspecific Incidental Brain Lesions. J Nucl Med. 2008;
49(5):730–7. https://doi.org/10.2967/jnumed.107.050005 PMID: 18413396
41. WeberWA,Wester H-J, Grosu AL, Herz M, Dzewas B, Feldmann H-J, et al. O-(2-[18F]Fluoroethyl)-l-
tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study.
Eur J Nucl Med. 2000; 27(5):542–9. https://doi.org/10.1007/s002590050541 PMID: 10853810
42. Pauleit D, Floeth FW, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller H-W, et al. O-(2-
[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral
gliomas. Brain. 2005; 128(3):678–87. https://doi.org/10.1093/brain/awh399 PMID: 15689365.
43. Gempt J, Bette S, Buchmann N, Ryang YM, Forschler A, Pyka T, et al. Volumetric Analysis of F-18-
FET-PET Imaging for Brain Metastases. World Neurosurg. 2015; 84(6):1790–7. https://doi.org/10.
1016/j.wneu.2015.07.067 PMID: 26255241.
44. Pichler R, Dunzinger A, WurmG, Pichler J, Weis S, Nussbaumer K, et al. Is there a place for FET PET
in the initial evaluation of brain lesions with unknown significance? Eur J Nucl MedMol Imaging. 2010;
37(8):1521–8. https://doi.org/10.1007/s00259-010-1457-6 PMID: 20396883.
PLOS ONE Reference for 18F-FET uptake of the human brain
PLOSONE | https://doi.org/10.1371/journal.pone.0230618 April 17, 2020 15 / 16
45. Salber D, Stoffels G, Oros-Peusquens A-M, Shah NJ, Reifenberger G, Hamacher K, et al. Comparison
of O-(2-18F-Fluoroethyl)-l-Tyrosine and l-3H-Methionine Uptake in Cerebral Hematomas. J Nucl Med.
2010; 51(5):790–7. https://doi.org/10.2967/jnumed.109.071423 PMID: 20395334
46. Nowosielski M, DiFranco MD, Putzer D, Seiz M, RecheisW, Jacobs AH, et al. An intra-individual com-
parison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoSOne. 2014; 9
(4):e95830. https://doi.org/10.1371/journal.pone.0095830 PMID: 24759867; PubMed Central PMCID:
PMC3997484.
47. Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D, et al. Stereotactic Comparison
among Cerebral Blood Volume, Methionine Uptake, and Histopathology in Brain Glioma. Am J Neurora-
diol. 2007; 28(3):455–61. PMID: 17353312.
48. Grosu A-L, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual com-
parison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in
patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011; 81(4):1049–58. https://
doi.org/10.1016/j.ijrobp.2010.07.002 PMID: 21570201.
49. Heiss P, Mayer S, Herz M,Wester HJ, Schwaiger M, Senekowitsch Schmidtke R. Investigation of trans-
port mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med.
1999; 40(8):1367–73. PMID: 10450690.
50. Gottler J, Lukas M, Kluge A, Kaczmarz S, Gempt J, Ringel F, et al. Intra-lesional spatial correlation of
static and dynamic FET-PET parameters with MRI-based cerebral blood volume in patients with
untreated glioma. Eur J Nucl Med Mol Imaging. 2017; 44(3):392–7. https://doi.org/10.1007/s00259-
016-3585-0 PMID: 27913827.
51. Blanc-Durand P, Van Der Gucht A, Verger A, Langen K-J, Dunet V, Bloch J, et al. Voxel-based 18F-
FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1
mutation status and survival in patients with gliomas. PLOSONE. 2018; 13(6):e0199379. https://doi.
org/10.1371/journal.pone.0199379 PMID: 29953478
52. Unterrainer M, Vettermann F, Brendel M, Holzgreve A, Lifschitz M, Zähringer M, et al. Towards stan-
dardization of 18F-FET PET imaging: do we need a consistent method of background activity assess-
ment? EJNMMI Research. 2017; 7(1):1–8. https://doi.org/10.1186/s13550-016-0252-1 PMID:
28058659
53. Marner L, Henriksen OM, Lundemann M, Larsen VA, Law I. Clinical PET/MRI in neurooncology: oppor-
tunities and challenges from a single-institution perspective. Clin Transl Imaging. 2017; 5(2):135–49.
https://doi.org/10.1007/s40336-016-0213-8 PMID: 28936429.
54. Galldiks N, Langen K-J. Amino acid PET in neuro-oncology: applications in the clinic. Expert Rev Anti-
cancer Ther. 2017; 17(5):395–7. https://doi.org/10.1080/14737140.2017.1302799 PMID: 28277832
55. Jadvar H, Colletti PM. Competitive advantage of PET/MRI. Eur J Radiol. 2014; 83(1):84–94. https://doi.
org/10.1016/j.ejrad.2013.05.028 PMID: 23791129
PLOS ONE Reference for 18F-FET uptake of the human brain
PLOSONE | https://doi.org/10.1371/journal.pone.0230618 April 17, 2020 16 / 16
